166 related articles for article (PubMed ID: 26984978)
1. Genetic variations of phenprocoumon metabolism in patients with ventricular assist devices.
Brehm K; Krumnau O; Heilmann C; Beyersdorf F
Eur J Cardiothorac Surg; 2016 Aug; 50(2):275-80. PubMed ID: 26984978
[TBL] [Abstract][Full Text] [Related]
2. Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism.
Brehm K; Schack J; Heilmann C; Blanke P; Geissler HJ; Beyersdorf F
Eur J Cardiothorac Surg; 2013 Aug; 44(2):309-14; discussion 314-5. PubMed ID: 23423913
[TBL] [Abstract][Full Text] [Related]
3. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.
Cadamuro J; Dieplinger B; Felder T; Kedenko I; Mueller T; Haltmayer M; Patsch W; Oberkofler H
Eur J Clin Pharmacol; 2010 Mar; 66(3):253-60. PubMed ID: 20020283
[TBL] [Abstract][Full Text] [Related]
4. VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.
Puehringer H; Loreth RM; Klose G; Schreyer B; Krugluger W; Schneider B; Oberkanins C
Eur J Clin Pharmacol; 2010 Jun; 66(6):591-8. PubMed ID: 20376629
[TBL] [Abstract][Full Text] [Related]
5. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
[TBL] [Abstract][Full Text] [Related]
6. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.
Nowak-Göttl U; Dietrich K; Schaffranek D; Eldin NS; Yasui Y; Geisen C; Mitchell LG
Blood; 2010 Dec; 116(26):6101-5. PubMed ID: 20833980
[TBL] [Abstract][Full Text] [Related]
7. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.
Schalekamp T; Brassé BP; Roijers JF; van Meegen E; van der Meer FJ; van Wijk EM; Egberts AC; de Boer A
Clin Pharmacol Ther; 2007 Feb; 81(2):185-93. PubMed ID: 17192772
[TBL] [Abstract][Full Text] [Related]
8. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
Beinema M; Brouwers JR; Schalekamp T; Wilffert B
Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
[TBL] [Abstract][Full Text] [Related]
10. Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study.
Brunner-Ziegler S; Jilma B; Magirr D; Sunder-Plassmann R; Giurgea GA; Hammer A; Margeta C; Brunner M; Koppensteiner R; Mannhalter C
Br J Haematol; 2014 Nov; 167(4):547-53. PubMed ID: 25142093
[TBL] [Abstract][Full Text] [Related]
11. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes.
Qazim B; Stöllberger C; Krugluger W; Dossenbach-Glaninger A; Finsterer J
J Thromb Thrombolysis; 2009 Aug; 28(2):211-4. PubMed ID: 18629445
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.
Nagler M; Angelillo-Scherrer A; Méan M; Limacher A; Abbal C; Righini M; Beer JH; Osterwalder J; Frauchiger B; Aschwanden M; Matter CM; Kucher N; Cornuz J; Banyai M; Husmann M; Staub D; Mazzolai L; Hugli O; Rodondi N; Aujesky D
J Thromb Haemost; 2017 Nov; 15(11):2165-2175. PubMed ID: 28834238
[TBL] [Abstract][Full Text] [Related]
13. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
An SH; Lee KE; Chang BC; Gwak HS
J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
[TBL] [Abstract][Full Text] [Related]
14. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
[TBL] [Abstract][Full Text] [Related]
15. Effects of vitamin K epoxide reductase complex 1 gene polymorphisms on warfarin control in Japanese patients with left ventricular assist devices (LVAD).
Nakagita K; Wada K; Mukai Y; Uno T; Nishino R; Matsuda S; Takenaka H; Terakawa N; Oita A; Takada M
Eur J Clin Pharmacol; 2018 Jul; 74(7):885-894. PubMed ID: 29781049
[TBL] [Abstract][Full Text] [Related]
16. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
Ghozlan MF; Foad DA; Darwish YW; Saad AA
Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing.
Werner D; Werner U; Wuerfel A; Grosch A; Lestin HG; Eschenhagen T; Rau T
Eur J Clin Pharmacol; 2009 Aug; 65(8):783-8. PubMed ID: 19319511
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort.
Camilleri E; Ghobreyal M; Bos MHA; Reitsma PH; Van Der Meer FJM; Swen JJ; Cannegieter SC; van Rein N
Pharmacotherapy; 2024 Jun; 44(6):416-424. PubMed ID: 38686648
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP2C9 and VKORC1 Gene Variants on Warfarin Response in Patients with Continuous-Flow Left Ventricular Assist Devices.
Topkara VK; Knotts RJ; Jennings DL; Garan AR; Levin AP; Breskin A; Castagna F; Cagliostro B; Yuzefpolskaya M; Takeda K; Takayama H; Uriel N; Mancini DM; Eisenberger A; Naka Y; Colombo PC; Jorde UP
ASAIO J; 2016; 62(5):558-64. PubMed ID: 27258224
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
Ufer M
Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
